NCT06571864Completed
AL Amyloidosis and Anti-CD38-Daratunumab
Source: ClinicalTrials.gov · Last updated 26 Aug 2024
Brief summary (registry, in English)
AL Amyloidosis and anti-CD38
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 14 (actual)
- First submitted
- 20 Aug 2024
- Start date
- 2 Jan 2022
- Primary completion date
- 2 Jan 2024
- Lead sponsor
- University of Turin, Italy
- Diseases
- Amyloidosis
- NCT number
- NCT06571864
What you commit to
- Study type: Interventional
- Participants enrolled: 14
- From 2 Jan 2022 to the primary completion date, 2 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Diagnosis of AL amyloidosis not biospy proven
Who the study is looking for
- Patients affected by AL amyloidosis
- Patients who were ineligible for high dose therapy and bone marrow transplantation due to age and/or frailty score.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| San Giovanni Bosco Hospital Coordinator of this site? Confirm its status | Turin | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.